Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
The purpose of this study is to assess the safety and effectiveness of the investigational drug ZEN003694 in people with advanced squamous cell lung cancer that continues to grow despite treatment and contains multiple copies of a gene called NSD3. ZEN003694 blocks a group of proteins called BET, which may counteract the effect of NSD3 on tumor growth. Blocking these proteins may slow or stop the growth of lung cancer. ZEN003694 is taken orally (by mouth).
Researchers are comparing RMC-6236 with docetaxel for the treatment of lung cancer. The people in this study have non-small cell lung cancer (NSCLC) that has spread beyond its original location. In addition, their tumors have a mutation (change) in the RAS gene.
Researchers want to find the best dose of INCB161734 to use in people with advanced cancer. The people in this study have solid tumors that have spread. In addition, their cancers have a genetic mutation (change) called KRAS G12D.
In this study, researchers want to find out how different amounts of aerobic training might improve cardiorespiratory fitness in people while they are treated for breast cancer. Cardiorespiratory fitness is important for the health of people receiving treatment for breast cancer. Aerobic exercise stimulates and strengthens the heart and lungs and improves how the body uses oxygen.
When people have Richter's transformation, their chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) changes into a more aggressive disease. Researchers are assessing a new drug combination for people with Richter's transformation that came back or keeps growing after treatment.
The standard approach to controlling pain after mastectomy includes intravenous and oral pain-relieving medications. In this study, researchers are determining if adding a long-acting local anesthetic, bupivacaine, into the wound at the end of the operation is more effective at reducing pain than the standard medications alone for women having a mastectomy on one side with no immediate reconstruction afterward.
Researchers are assessing petosemtamab given alone or with standard chemotherapy in people with advanced colorectal cancer. The people in this study have colorectal cancer that is inoperable (cannot be removed with surgery) or has metastasized (spread).
The purpose of this study is to find the highest dose of the investigational treatment UCART22 that can be given safely in children and young adults with B-cell acute lymphoblastic leukemia (ALL) that has come back or continued to grow despite treatment. UCART22 is a form of CAR T-cell therapy. It is made from white blood cells (T cells) from healthy donors. The T cells are genetically modified in a laboratory to identify and destroy cancer cells containing a protein called CD22.
Researchers are assessing the iberdomide with belantamab mafodotin and dexamethasone in people with multiple myeloma. The people in this study have multiple myeloma that came back or keeps growing even with treatment.
The purpose of this study is to find out how cancer treatments (chemotherapy and/or radiation therapy) affect reproductive and sexual health in people with early-onset colorectal cancer (diagnosed before age 50). Researchers will observe and track changes in hormone levels and in sexual and reproductive health in the study participants. This information will help them learn more about how cancer treatments affect reproductive and sexual health, including the ability to have children (fertility).
